Excellent Article on CBD

For those who like to do there own research: Credit For this Article belongs to the World Health Organization.

The World Health Organization on CBD!

Table of contents:
1. Pharmacokinetics
2. Immune Support
3. Pregnancy
4. Dependency & Abuse
5. Alzheimer’s Disease
6. Parkinson’s Disease
7. Multiple Sclerosis
8. Huntington’s Disease
9. Hypoxia-ischemia injury
10. Pain
11. Psychosis
12. Anxiety
13. Depression
14. Cancer
15. Nausea
16. Inflammatory Diseases
17. Rheumatoid Arthritis
18. Infection
19. Inflammatory bowel and Crohn's diseases
20. Cardiovascular Disease
21. Diabetic complications
22. Epilepsy

1. Pharmacokinetics
“Oral delivery of oil-based CBD has been assessed in humans. Bioavailability from oral, oil-based delivery was estimated to be 6% due to significant first-pass metabolism. Probably due to its poor aqueous solubility, the absorption of CBD from the gastrointestinal tract is erratic, and the resulting pharmacokinetic profile is variable. Studies show CBD may preferentially accumulate in adipose [fatty] tissues due to its high lipophilicity [solubility in fat]” (World Health Organization, 2017).

“Human beings are mostly water, ranging from about 75 percent of body mass in infants to about 50–60 percent in adult men and women, to as low as 45 percent in old age. The percent of body water changes with development, because the proportions of the body given over to each organ and to muscles, fat, bone, and other tissues change from infancy to adulthood (Figure 1). Your brain and kidneys have the highest proportions of water, which composes 80–85 percent of their masses. In contrast, teeth have the lowest proportion of water, at 8–10 percent.”
https://opentextbc.ca/…/26-1-body-fluids-and-fluid-compart…/
https://water.usgs.gov/edu/propertyyou.html

2. Immune Support
Immune stimulation may occur at lower concentrations, but there is evidence of immune suppression at higher concentrations (World Health Organization, 2017).

3. Pregnancy
CBD has no effect on embryonic development (World Health Organization, 2017).

4. Dependency & Abuse
Controlled, human studies regarding the potential physical dependence effects (e.g. withdrawal and tolerance) of cannabidiol have not been reported. Additionally, CBD is not associated with abuse potential (World Health Organization, 2017).

5. Alzheimer's disease
Antinflammatory, antioxidant, antiapoptotic in in vitro and in vivo models of Aβ-evoked neuroinflammatory and neurodegenerative responses (World Health Organization, 2017).

6. Parkinson's disease
Attenuation of the dopaminergic impairment in vivo; neuroprotection; improvement of psychiatric rating and reduction of agitation, nightmare and aggressive behavior in patients (World Health Organization, 2017).

7. Multiple sclerosis
Improved signs of EAE in mice, antinflammatory and immunomodulatory properties (World Health Organization, 2017).

8. Huntington's disease
Neuroprotective and antioxidant in mice transgenic models; no significant clinically important differences in patients (World Health Organization, 2017).

9. Hypoxia-ischemia injury
Short term neuroprotective effects; inhibition of excitotoxicity, oxidative stress and inflammation in vitro and in rodent models (World Health Organization, 2017).

10. Pain
Analgesic effect in patients with neuropathic pain resistant to other treatments (World Health Organization, 2017).

11. Psychosis
Attenuation of the behavioural and glial changes in animal models of schizophrenia; anti-psychotic properties on ketamine-induced symptoms (World Health Organization, 2017).

12. Anxiety
Reduction of muscular tension, restlessness, fatigue, problems in concentration, improvement of social interactions in rodent models of anxiety and stress; reduced social anxiety in patients (World Health Organization, 2017).

13. Depression
Anti-depressant effect in genetic rodent model of depression (World Health Organization, 2017).

14. Cancer
Antiproliferative and anti-invasive actions in a large range of cancer types; induction of autophagy mediated cancer cell death; chemopreventive effects (World Health Organization, 2017).

15. Nausea
Suppression of nausea and conditioned gaping in rats (World Health Organization, 2017).

16. Inflammatory diseases
Anti-inflammatory properties in several in vitro and in vivo models; inhibition of inflammatory cytokines and pathways (World Health Organization, 2017).

17. Rheumatoid arthritis
Inhibition of TNF-α in an animal model (World Health Organization, 2017).

18. Infection
Activity against methicillin-resistant Staphylococcus aureus (World Health Organization, 2017).

19. Inflammatory bowel and Crohn's diseases
Inhibition of macrophage recruitment and TNF-α secretion in vivo and ex vivo; reduction in disease activity index in Crohn's patients (World Health Organization, 2017).

20. Cardiovascular diseases
Reduced infarct size through anti-oxidant and anti-inflammatory properties in vitro and in vivo (World Health Organization, 2017).

21. Diabetic complications
Attenuation of fibrosis and myocardial dysfunction (World Health Organization, 2017).

22. Epilepsy
CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials (World Health Organization, 2017).

Reference:

World Health Organization
https://www.who.int/…/acc…/controlled-substances/5.2_CBD.pdf

 

Leave a Comment

Your email address will not be published. Required fields are marked *